Fighting Cardiac Fibrosis with CAR T Cells
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Autologous chimeric antigen receptor T cells, which are engineered to bind and kill cells that express a specific antigen, are effective in the treatment of certain cancers. A recent study involving a mouse model shows that CAR T cells can be generated in vivo and may reduce fibrosis after myocardial injury.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“On the other hand, other efforts to target fibrogenic cells in the heart by targeting cell surface FAP-1 (fibroblast activating protein) are very encouraging, and may be adaptable to liver disease.147,148”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [147]
Citations
Cites
Fibrosis–a common pathway to organ injury and failure
Rockey, D. C., Bell, P. D., & Hill, J. A. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1300575 · Cited by 1,428
CAR T cells produced in vivo to treat cardiac injury
Rurik, J. G., Tombácz, I., Yadegari, A., Méndez Fernández, P. O., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., et al. (2022) · Science · doi:10.1126/science.abm0594 · Cited by 1,400
Senolytic CAR T cells reverse senescence-associated pathologies
Amor, C., Feucht, J., Leibold, J., Ho, Y.-J., Zhu, C., Alonso-Curbelo, D., Mansilla-Soto, J., Boyer, J. A., Li, X., Giavridis, T., et al. (2020) · Nature · doi:10.1038/s41586-020-2403-9 · Cited by 1,098
Self-citationCAR T Cells Produced in vivo to Treat Cardiac Injury
Rurik, J. G., Tombácz, I., Yadegari, A., Fernández, P. O. M., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., et al. (2023) · Book Publisher International (a part of SCIENCEDOMAIN International) · doi:10.9734/bpi/mono/978-81-19039-63-0/ch19 · Cited by 929
CAR T Cells Produced in vivo to Treat Cardiac Injury
Rurik, J. G., Tombácz, I., Yadegari, A., Fernández, P. O. M., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., et al. (2023) · HAL · Cited by 926
Targeting cardiac fibrosis with engineered T cells
Aghajanian, H., Kimura, T., Rurik, J. G., Hancock, A. S., Leibowitz, M. S., Li, L., Scholler, J., Monslow, J., Lo, A., Han, W., et al. (2019) · Nature · doi:10.1038/s41586-019-1546-z · Cited by 801
Fibrosis — A Common Pathway to Organ Injury and Failure
(2015) · New England Journal of Medicine · doi:10.1056/nejmc1504848 · Cited by 284
Better living through chemistry: CRISPR/Cas engineered T cells for cancer immunotherapy
Wellhausen, N., Agarwal, S., Rommel, P. C., Gill, S. I., & June, C. H. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.10.008 · Cited by 28
Cited by
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Tacke, F., Puengel, T., Loomba, R., & Friedman, S. L. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.038 · Cited by 321
Self-citationTreatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy
Morfino, P., Aimo, A., Castiglione, V., Gálvez‐Montón, C., Emdin, M., & Bayés‐Genís, A. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10279-x · Cited by 72
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease
Schwabe, R. F., Tacke, F., Sugimoto, A., & Friedman, S. L. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101421 · Cited by 70
Self-citationHuston, P. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.904107 · Cited by 42
“It has recently been estimated that 40% of all deaths in the industrialized world is due to fibrosis (Friedman, 2022).”
BackgroundAntifibrotic effects of sodium-glucose cotransporter-2 inhibitors: A comprehensive review
Shakour, N., Karami, S., Iranshahi, M., Butler, A. E., & Sahebkar, A. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102934 · Cited by 35
Nanomedicines for cardiovascular diseases: Lessons learned and pathways forward
Mao, Y.-A., Shi, X., Sun, P., Spanos, M., Zhu, L., Chen, H., Wang, X., Su, C., Jin, Y., Wang, X., et al. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123271 · Cited by 29
Drugs for treating myocardial fibrosis
Ren, Z., Zhang, Z., Ling, L., Liu, X., & Wang, X. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1221881 · Cited by 28
“Some drugs that target these pathways, such as RAAS inhibitors, have been proven to be effective in reducing ECM deposition in the myocardium (Friedman, 2022).”
BackgroundCardiac fibrosis in oncologic therapies
Packard, R. R. S. (2022) · Current Opinion in Physiology · doi:10.1016/j.cophys.2022.100575 · Cited by 23
Rossin, D., Vanni, R., Iacono, M. L., Cristallini, C., Giachino, C., & Rastaldo, R. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051408 · Cited by 21
“Although these treatments have decreased the rate of morbidity and mortality, they are, however, uncapable of avoiding ventricular remodelling and progressive fibrosis [2].”
Xiong, H., & Guo, J. (2025) · Pharmaceuticals · doi:10.3390/ph18040507 · Cited by 24
“A remarkably elegant strategy by the same group built upon the conventional CAR T approach, instead developing a method for the in vivo programming of CAR T cells [98–101].”
Ferrer‐Curriu, G., Soler‐Botija, C., Charvátová, S., Motais, B., Roura, S., Gálvez‐Montón, C., Tortajada, M., Egea, O. I., Emdin, M., Lupón, J., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114061 · Cited by 22
Gaydarski, L., Petrova, K., Stanchev, S., Pelinkov, D., Iliev, A. A., Dimitrova, I. N., Kirkov, V., Landzhov, B. V., & Stamenov, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094022 · Cited by 22
Emerging CAR immunotherapies: broadening therapeutic horizons beyond cancer
Sueangoen, N., & Prasongtanakij, S. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01820-x · Cited by 16
“Furthermore, CAR T cells targeting fibroblast activation protein have been investigated for treating cardiac fibrosis [130, 131] and found to reduce fibrosis in mouse models [132].”
Ye, B., Hu, Y., ZHANG, M., & Huang, H. (2022) · Journal of Zhejiang University (Medical Sciences) · doi:10.3724/zdxbyxb-2022-0047 · Cited by 20
mRNA lipid nanoparticles in CAR-T therapy: a novel strategy to improve efficacy
Zhao, Z., Li, M., Zheng, X., Gao, P., Huang, C., Yu, Q., Jin, L., Zhang, L., Zhu, D., & Li, F. (2025) · Nanotechnology · doi:10.1088/1361-6528/add482 · Cited by 7
Applications and Opportunities for Immune Cell CAR Engineering in Comparative Oncology
Rotolo, A., & Atherton, M. J. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3690 · Cited by 9
Wu, C., Chen, X., Yang, L., Sun, H., Bao, S., Li, H., Zheng, L., Zeng, H., Li, R., & Peng, Y. (2024) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2024.25 · Cited by 5
“71, 72), increasing evidence from clinical and animal studies suggests that ET-based CR should be taken into consideration to prevent the progression of adverse CF (Refs.”
Smart lipid nanoparticles: the chemistry driving targeted therapeutics
Abbrederis, N., Paloglou, D., & Astakhova, K. (2025) · Trends in Chemistry · doi:10.1016/j.trechm.2025.09.011 · Cited by 5
Li, X., Jin, K., Fang, J., Ma, X., He, J., Lu, A., Jia, Z., & Shi, A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1835197 · Cited by 4
Zhong, G., Luo, Y., Wang, M., Yu, Z., Zou, X., Wang, G., Chen, F., & Yu, Y. (2025) · Engineered Regeneration · doi:10.1016/j.engreg.2025.03.002 · Cited by 3
Lasting consequences of cigarette smoking on the heart
Amin, G., Booz, G. W., & Zouein, F. A. (2024) · Acta Physiologica · doi:10.1111/apha.14166 · Cited by 3
“9 Noteworthy, the selection of an appropriate therapeutic intervention for smoking cessation is dependent upon the temporal patterns associated with cessation.”
BackgroundWu, Z., Zou, X., Chen, C., Zhou, M., Yue, X., Guo, D., Gao, Y., Ma, C., Han, Q., Yang, D., et al. (2026) · Cell stem cell · doi:10.1016/j.stem.2026.04.003 · Cited by 4
Zhong, G., Luo, Y., Zhao, J., Wang, M., Yang, F., Huang, J., Zou, L., Zou, X., Wang, Q., Chen, F., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.06.490932 · Cited by 3
“mRNA technology, led by molecular backbone modifications and mRNA enhanced cell therapy such as the new CAT-T therapy[23-25] have sparked very strong interests in”
BackgroundCardiac Immunotherapy, Immuno-Cardiology, and the Future of Cardiovascular Pharmacology
Biondi‐Zoccai, G., Weber, B., Abbate, A., & Booz, G. W. (2025) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001687 · Cited by 2
Liver Steatosis: From Lipotoxicity to Cellular Damage
Puengel, T., & Tacke, F. (2024) · Springer eBooks · doi:10.1007/978-981-97-9519-2_4 · Cited by 3
In vivo CAR-M therapy: advancing precision delivery and programmable immune remodeling
Wang, S., Zhou, L., Chen, X., Xu, Z., Chen, Y., Lin, N., & Tu, J. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02962-5 · Cited by 3
“Current treatments (e.g., reperfusion, β-blockers, and RAAS inhibitors) primarily reduce cardiac load and inhibit neuroendocrine activation, yet they lack direct intervention against pathogenic fibroblasts [115].”
Dubey, N., Vishwakarma, V. K., Verma, A., Goyal, A., Yadav, H. N., Reeta, K. H., Yadav, S. C., & Parakh, N. (2025) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70347 · Cited by 1
“It has been shown that some medications, which include RAAS inhibitors, which target these pathways, are useful in lowering ECM deposition in the heart [41].”
Multifunctional nucleic acid-based therapy in fibrosis-related diseases
Cheng, J., Zhou, M., Guo, Y., Yang, Y., Lv, W., Renzeng, Y. A. N. G., Xie, Y., Jiang, Y., Yao, L., Qi, C., et al. (2026) · Science China Chemistry · doi:10.1007/s11426-025-3231-6
Metadata
- Authors
- Friedman, S. L.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Friedman, Scott L.
- ORCID
- Friedman, Scott L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-04-21
- Volume
- 386
- Issue
- 16
- Pages
- 1576-1578
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4224285902
- Cited by
- 28
- References
- 7
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 4 · 2023: 4 · 2022: 6
- FWCI
- 4.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
- Keywords
- myocardial fibrosis, chimeric antigen receptor T cells, CAR T-cell therapy, myocardial injury, mouse model
- MeSH terms
- Receptors, Chimeric Antigen, Fibrosis, Heart Diseases, Humans, T-Lymphocytes, Immunotherapy, Adoptive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.